Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.55 |
| ▸ | CTSS | P25774 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.52 |
| ▸ | GCK | P35557 | 10/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | METAP1 | P53582 | 1/20 | 0.46 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12228038 | 1.00 | CTSK (0.55) | CTSKCTSSPOLBAAK1GCK | |
| SCHEMBL2672699 | 0.88 | POLB (0.48) | CTSKCTSSPOLBGCKEPHX2 | |
| SCHEMBL9072797 | 0.82 | CTSS (0.53) | CTSKCTSSAAK1GCKFFAR2 | |
| SCHEMBL2513951 | 0.82 | ALDH1A1 (0.46) | GCKMETAP1 | |
| SCHEMBL6820524 | 0.81 | HSPA5 (0.61) | CTSKCTSSMETAP1FFAR2 | |
| SCHEMBL27192711 | 0.80 | CTSS (0.58) | CTSKCTSSAAK1 | |
| SCHEMBL27192706 | 0.80 | CTSS (0.58) | CTSKCTSSAAK1 | |
| SCHEMBL27192808 | 0.80 | CTSS (0.55) | CTSKCTSSAAK1GCK | |
| SCHEMBL27192669 | 0.80 | CTSS (0.55) | CTSKCTSSAAK1GCK | |
| SCHEMBL14418794 | 0.77 | ALDH1A1 (0.52) | CTSKMETAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173645-B2 | Glucokinase activators | TAKEDA SAN DIEGO, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173645-B2 | Glucokinase activators | TAKEDA SAN DIEGO, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20090099163-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099163-A1 | GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2008116107-A2 | PIPERAZINE DERIVATIVES AS GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008116107-A2 | PIPERAZINE DERIVATIVES AS GLUCOKINASE ACTIVATORS | TAKEDA SAN DIEGO, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099163-A1 | GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | CTSK 100/4885CTSS 843/4885POLB 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.